Allspring Global Investments Holdings LLC Sells 146,925 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Allspring Global Investments Holdings LLC lessened its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 51.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 137,764 shares of the company’s stock after selling 146,925 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Amneal Pharmaceuticals were worth $836,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Rubric Capital Management LP increased its stake in shares of Amneal Pharmaceuticals by 54.7% in the 3rd quarter. Rubric Capital Management LP now owns 4,024,500 shares of the company’s stock valued at $16,983,000 after purchasing an additional 1,423,121 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Amneal Pharmaceuticals by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock valued at $57,174,000 after purchasing an additional 412,599 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Amneal Pharmaceuticals by 122.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 515,233 shares of the company’s stock worth $2,174,000 after acquiring an additional 283,524 shares during the last quarter. EAM Investors LLC bought a new stake in Amneal Pharmaceuticals during the 3rd quarter worth $972,000. Finally, LSV Asset Management grew its position in Amneal Pharmaceuticals by 10.5% during the 3rd quarter. LSV Asset Management now owns 1,429,300 shares of the company’s stock worth $6,032,000 after acquiring an additional 136,100 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on AMRX shares. Barclays boosted their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. The Goldman Sachs Group boosted their price objective on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research report on Monday, March 4th. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $7.31.

Amneal Pharmaceuticals Stock Up 12.0 %

Shares of AMRX opened at $6.05 on Thursday. The company has a market capitalization of $1.86 billion, a PE ratio of -19.52 and a beta of 1.33. Amneal Pharmaceuticals, Inc. has a 12 month low of $1.64 and a 12 month high of $6.46. The stock’s 50-day moving average price is $5.72 and its two-hundred day moving average price is $5.17. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. The company had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.5 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.